Stephens Consulting’s Acadia Pharmaceuticals ACAD Stock Holding History

Stephens Consulting’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-25	Closed	-$416	–	1190
2025 Q1	$416	Buy	+25	New	+$454	﹤0.01%	995

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Stephens Consulting's ACAD Position: Q2 2025 in Review

Stephens Consulting sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 25 shares — an estimated $416 sold.

Stephens Consulting first reported a position in ACAD in Q1 2025 and held it in 1 quarter. The position peaked at $416 in Q1 2025. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

Stephens Consulting reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 25 Acadia Pharmaceuticals shares in Q2 2025, an estimated $416.
Stephens Consulting first reported a position in Acadia Pharmaceuticals in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Acadia Pharmaceuticals position peaked at $416 in Q1 2025.
311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.